FY2025 Earnings Estimate for Envista Issued By William Blair

Envista Holdings Corporation (NYSE:NVST) – Equities researchers at William Blair upped their FY2025 earnings per share (EPS) estimates for shares of Envista in a research note issued to investors on Friday, October 31st. William Blair analyst B. Vazquez now forecasts that the company will post earnings of $1.13 per share for the year, up from their previous forecast of $1.10. The consensus estimate for Envista’s current full-year earnings is $1.00 per share. William Blair also issued estimates for Envista’s Q3 2026 earnings at $0.31 EPS, FY2026 earnings at $1.21 EPS, Q1 2027 earnings at $0.28 EPS, Q2 2027 earnings at $0.30 EPS, Q3 2027 earnings at $0.32 EPS and FY2027 earnings at $1.31 EPS.

Envista (NYSE:NVST) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Envista had a return on equity of 4.84% and a net margin of 2.11%.The business had revenue of $669.90 million for the quarter, compared to analyst estimates of $639.49 million. During the same quarter in the previous year, the firm earned $0.12 EPS. The company’s quarterly revenue was up 11.5% compared to the same quarter last year.

NVST has been the topic of several other research reports. UBS Group lifted their price target on Envista from $18.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, July 29th. Weiss Ratings restated a “sell (d)” rating on shares of Envista in a report on Wednesday, October 8th. Morgan Stanley boosted their price objective on shares of Envista from $16.00 to $17.00 and gave the company an “equal weight” rating in a report on Friday, August 1st. Evercore ISI restated an “outperform” rating on shares of Envista in a report on Friday. Finally, Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Envista has an average rating of “Hold” and a consensus price target of $21.33.

Envista Stock Up 0.4%

NYSE NVST opened at $20.17 on Monday. Envista has a 52 week low of $14.22 and a 52 week high of $22.68. The company has a quick ratio of 2.08, a current ratio of 2.44 and a debt-to-equity ratio of 0.46. The business’s fifty day simple moving average is $20.48 and its 200-day simple moving average is $19.49. The firm has a market cap of $3.35 billion, a PE ratio of 63.04, a P/E/G ratio of 1.09 and a beta of 1.01.

Hedge Funds Weigh In On Envista

Several institutional investors have recently bought and sold shares of NVST. Alliancebernstein L.P. grew its position in shares of Envista by 1,985.1% during the first quarter. Alliancebernstein L.P. now owns 4,550,789 shares of the company’s stock worth $78,547,000 after buying an additional 4,332,541 shares in the last quarter. Holocene Advisors LP acquired a new position in shares of Envista during the second quarter worth about $43,936,000. Norges Bank acquired a new position in shares of Envista during the second quarter worth about $40,229,000. Dimensional Fund Advisors LP grew its position in shares of Envista by 24.0% during the first quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company’s stock worth $144,760,000 after buying an additional 1,625,206 shares in the last quarter. Finally, Pzena Investment Management LLC grew its position in shares of Envista by 160.7% during the first quarter. Pzena Investment Management LLC now owns 2,294,257 shares of the company’s stock worth $39,599,000 after buying an additional 1,414,080 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.